Health Care
AMGN · Amgen
$414.61 Close · 2026-09-25
Close50-day avg200-day avg
Short-term view (1–4 weeks)
BuyRank #31 of 8564
+ Strengths
- + buyers in control this week
- + RSI in the healthy 50–70 momentum zone
- + MACD turning up (bullish crossover)
− Risks
- No standout weaknesses
Entry, stop and target levels plus the full factor breakdown are free with an account.Join free
Long-term view (6–24 months)
BuyRank #4 of 8571
+ Strengths
- + persistent 12-month uptrend
- + 50-day above 200-day (golden-cross regime)
- + excellent return per unit of risk
− Risks
- − heavily leveraged balance sheet
Entry, stop and target levels plus the full factor breakdown are free with an account.Join free
Fundamentals
- Market cap
- $224.2B
- P/E (TTM)
- 25.6
- Return on equity
- 89.3%
- Revenue growth (YoY)
- +9.1%
- Net margin
- 22.9%
- Debt / equity
- 4.90
- Dividend yield
- 2.32%
- Beta
- 0.45
- 52-week high
- $447.03
- 52-week low
- $269.77
Latest news
Company news is included with a free account.
Model output for education and research — not financial advice or a personal recommendation. Always do your own research and manage your risk.